![Brian Druker steps down as CEO of OHSU Knight Cancer Center](https://cdn.cancerletter.com/media/2024/12/06155445/story-1-4x3-1.png)
![Brian Druker steps down as CEO of OHSU Knight Cancer Center](https://cdn.cancerletter.com/media/2024/12/06155445/story-1-4x3-1.png)
Cover Story
Conversation with The Cancer Letter
On Dec. 3, the faculty and staff members at the OHSU Knight Cancer Institute received an email from Brian J. Druker, the institution’s star scientist, former director, and current CEO, informing them that he would be stepping down from his executive role.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
NCI Trials
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
NCI Trials for December 2024
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Trump administration caps indirect costs at 15%, inviting injunctions, congressional scrutiny
The move could gut academic cancer research - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- Tracking Trump’s early impact on cancer policy
Research and care disrupted, NCI programs face unpredictable future - Senate Finance Committee advances RFK Jr. to likely confirmation, with Bill Cassidy (R-LA) casting the deciding vote
- Beyond the $500B Stargate Project: The frontier of AI in oncology beckons
- “Page Not Found:” HHS agencies purge web pages that hint at DEI, health equity, and gender
Medical group sues over removing “information used every day by health professions”